298 related articles for article (PubMed ID: 17547437)
1. Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer.
Philip R; Murthy S; Krakover J; Sinnathamby G; Zerfass J; Keller L; Philip M
J Proteome Res; 2007 Jul; 6(7):2509-17. PubMed ID: 17547437
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis.
Fernández Madrid F
Cancer Lett; 2005 Dec; 230(2):187-98. PubMed ID: 16297705
[TBL] [Abstract][Full Text] [Related]
3. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.
Morse MA; Secord AA; Blackwell K; Hobeika AC; Sinnathamby G; Osada T; Hafner J; Philip M; Clay TM; Lyerly HK; Philip R
Clin Cancer Res; 2011 May; 17(10):3408-19. PubMed ID: 21300761
[TBL] [Abstract][Full Text] [Related]
4. [Molecular diagnostics of ovarian cancer using proteome techniques].
Vlasova MA; Moshkovskiĭ SA; Safarova MP; Makarov OV; Archakov AI
Biomed Khim; 2005; 51(4):367-83. PubMed ID: 16223028
[TBL] [Abstract][Full Text] [Related]
5. Proteomic identification of autoantibodies in sera from patients with ovarian cancer as possible diagnostic biomarkers.
Yoneyama K; Kojima S; Kodani Y; Yamaguchi N; Igarashi A; Kurose K; Kawase R; Takeshita T; Hattori S; Nagata K
Anticancer Res; 2015 Feb; 35(2):881-9. PubMed ID: 25667470
[TBL] [Abstract][Full Text] [Related]
6. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.
Karabudak AA; Hafner J; Shetty V; Chen S; Secord AA; Morse MA; Philip R
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1757-70. PubMed ID: 23999876
[TBL] [Abstract][Full Text] [Related]
7. Immuno-proteomic discovery of tumor tissue autoantigens identifies olfactomedin 4, CD11b, and integrin alpha-2 as markers of colorectal cancer with liver metastases.
Yang Q; Bavi P; Wang JY; Roehrl MH
J Proteomics; 2017 Sep; 168():53-65. PubMed ID: 28669815
[TBL] [Abstract][Full Text] [Related]
8. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
[TBL] [Abstract][Full Text] [Related]
9. Exploring the immunoproteome for ovarian cancer biomarker discovery.
Martin K; Ricciardelli C; Hoffmann P; Oehler MK
Int J Mol Sci; 2011 Jan; 12(1):410-28. PubMed ID: 21339995
[TBL] [Abstract][Full Text] [Related]
10. Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells.
Shetty V; Nickens Z; Testa J; Hafner J; Sinnathamby G; Philip R
J Proteomics; 2012 Jun; 75(11):3270-90. PubMed ID: 22504797
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
[TBL] [Abstract][Full Text] [Related]
12. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
13. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
[TBL] [Abstract][Full Text] [Related]
14. Serum Profiling for Identification of Autoantibody Signatures in Diseases Using Protein Microarrays.
Gupta S; Manubhai KP; Mukherjee S; Srivastava S
Methods Mol Biol; 2017; 1619():303-315. PubMed ID: 28674893
[TBL] [Abstract][Full Text] [Related]
15. Identifying autoantigens as theranostic targets: antigen arrays and immunoproteomics approaches.
Tassinari OW; Caiazzo RJ; Ehrlich JR; Liu BC
Curr Opin Mol Ther; 2008 Apr; 10(2):107-15. PubMed ID: 18386222
[TBL] [Abstract][Full Text] [Related]
16. [Serum autoantibodies profiling and early-stage cancer detection].
Desmetz C; Lacombe J; Mange A; Maudelonde T; Solassol J
Med Sci (Paris); 2011; 27(6-7):633-8. PubMed ID: 21718648
[TBL] [Abstract][Full Text] [Related]
17. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer.
Kim S; Cho H; Nam EJ; Kim SW; Kim YT; Park YW; Kim BW; Kim JH
Genes Chromosomes Cancer; 2010 Jul; 49(7):585-95. PubMed ID: 20461751
[TBL] [Abstract][Full Text] [Related]
20. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma.
Fujita Y; Nakanishi T; Hiramatsu M; Mabuchi H; Miyamoto Y; Miyamoto A; Shimizu A; Tanigawa N
Clin Cancer Res; 2006 Nov; 12(21):6415-20. PubMed ID: 17085654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
